v3.26.1
Collaboration and License Agreements - License Agreement with Astellas US LLC (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended
Apr. 15, 2026
Jun. 30, 2026
Jun. 30, 2026
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Global development costs shared (as a percent) 40.00%    
Sanofi Agreement      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Asset acquisition, milestone payment   $ 48,000  
Astellas      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Upfront payments   240,000 $ 240,000
Sale of stock (in shares) 7,239,382    
Issuance of common stock $ 75,000    
Net proceeds received $ 75,700    
Sale of stock (in USD per share) $ 10.46    
Discount on shares $ 700    
Global development costs shared (as a percent) 60.00%    
Maximum future development, regulatory and ex-US sales milestone payments $ 1,390,000    
Maximum future development, regulatory and sales milestones payments 1,390,000    
Potential amount 1,620,000    
Astellas | License and collaboration revenue      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Upfront payments $ 239,300    
Astellas | VIR‑5500 Program License      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Decrease in research and development     5,000
Astellas | Astellas Agreements      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Credit to prepaid expenses and other current assets   $ 5,000 $ 5,000